EFFECTS OF HALF-DOSE PHOTODYNAMIC THERAPY ON CHRONIC CENTRAL SEROUS CHORIORETINOPATHY WITH OR WITHOUT MACULAR NEOVASCULARIZATION ASSESSED USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY

*Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan;

†Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan; and

‡Department of Ophthalmology, Fujita Health University School of Medicine, Toyoake, Japan.

Reprint requests: Jun Takeuchi, MD, PhD, Department of Ophthalmology, Nagoya University Graduate School of Medicine, 65Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan; e-mail: [email protected]

Supported by the Japan Society for the Promotion of Science, KAKENHI, (grant number: JP 20K09765).

None of the authors has any financial/conflicting interests to disclose.

Koichi Nakamura: None; Jun Takeuchi: Novartis (R), Santen (R), Bayer (R), and Senju (R); Keiko Asai: None; Yuyako Nakano: None; Etsuyo Horiguchi: None; Yosuke Taki: None; Hikaru Ota: None; Yasuki Ito: the Aichi Ophthalmologists Association (R), Bayer (R), Canon (R), ZEISS (R), Kowa (R), Novartis (R), Okazaki City Medical Association (R), Pfizer (R), and Santen (R); Hiroko Terasaki: ZEISS (N), Otsuka (F,R), Kowa (F,R), Santen (F,R), Senju (F,R), Sanof (F,R), Alcon (F,R), Novartis (F,R), ROHTO (F,R), Wakamoto (F,R), Bayer (R), HOYA (F), and Johnson & Johnson (F); Keiko Kataoka: Novartis (R), Santen (R), Bayer (R), Senju (R), Boehringer Ingelheim (R), and Otsuka (R); Koji M Nishiguchi: Takara bio (F), Takeda pharmaceutical (F), JCR Pharma (F), Alcon (F, R), Bayer (F, R), Novartis (F, R), Santen (F, R), Chugai Pharma (R), Kowa (F, R), Senju (F, R), Otsuka (F, R), Wakamoto (F, R), HOYA (F), AMO (F), Tomey (F), JFC Sales Plan (F), KYOWA (F), YAGAMI (F), Nitten Pharma (F), and a single AAV vector (P).

留言 (0)

沒有登入
gif